Dyne Therapeutics, Inc. (DYN)
2025-06-30 | ||||
|---|---|---|---|---|
| Unrealized gains (losses) on marketable securities, net | 11 | |||
| Other income (expense), net | -1,597 | |||
| Interest income | 6,625 | |||
| Interest expense | 94 | |||
| Total other income (expense), net | 4,934 | |||
| Research and development | 99,236 | |||
| General and administrative | 16,555 | |||
| Total operating expenses | 115,791 | |||
| Loss from operations | -115,791 | |||
| Net loss | -110,857 | |||
| Comprehensive loss | -110,846 | |||
| Net loss per share - basic | -0.97 | |||
| Net loss per share - diluted | -0.97 | |||